TY - JOUR
T1 - Colchicina, perspectivas de un viejo amigo para la reumatología en la COVID-19
T2 - una revisión exploratoria
AU - Tuta-Quintero, Eduardo
AU - Vega-Corredor, María Camila
AU - Perdomo-Rodríguez, Laura Sofía
AU - Pimentel, Juan
N1 - Publisher Copyright:
© 2021 Asociación Colombiana de Reumatología
PY - 2021
Y1 - 2021
N2 - Introduction: Colchicine is widely used to treat inflammatory diseases such as gout and Mediterranean fever. Due to its immunomodulatory capacity, it could play an important role in the treatment of COVID-19. Objective: To explore the current available medical evidence, published until 28 December 2020, regarding the efficacy and safety of colchicine in the treatment of patients with confirmed SARS-CoV-2 infection. Material and methods: Scoping review of the literature that included PubMed and Scopus. Records of clinical trials and publications with empirical data (observational and experimental studies) in English and Spanish were included. Results: A total of 33 clinical trials and 6 publications were found: prospective (n = 2) and retrospective (n = 2) cohort studies, randomised clinical trials (n = 1) and case-control studies (n = 1). The total number of participants in the trials is 46,324 individuals, 73% (24/33) of the studies are recruiting participants and 51% (17/33) are phase 3 studies. Conclusions: One clinical trial reports a decrease in prognostic inflammatory markers and length of hospital stay in SARS-CoV-2 infection. The ongoing clinical trials will clarify the efficacy and safety of colchicine for the management of patients with COVID-19.
AB - Introduction: Colchicine is widely used to treat inflammatory diseases such as gout and Mediterranean fever. Due to its immunomodulatory capacity, it could play an important role in the treatment of COVID-19. Objective: To explore the current available medical evidence, published until 28 December 2020, regarding the efficacy and safety of colchicine in the treatment of patients with confirmed SARS-CoV-2 infection. Material and methods: Scoping review of the literature that included PubMed and Scopus. Records of clinical trials and publications with empirical data (observational and experimental studies) in English and Spanish were included. Results: A total of 33 clinical trials and 6 publications were found: prospective (n = 2) and retrospective (n = 2) cohort studies, randomised clinical trials (n = 1) and case-control studies (n = 1). The total number of participants in the trials is 46,324 individuals, 73% (24/33) of the studies are recruiting participants and 51% (17/33) are phase 3 studies. Conclusions: One clinical trial reports a decrease in prognostic inflammatory markers and length of hospital stay in SARS-CoV-2 infection. The ongoing clinical trials will clarify the efficacy and safety of colchicine for the management of patients with COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85105427355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105427355&partnerID=8YFLogxK
U2 - 10.1016/j.rcreu.2021.02.002
DO - 10.1016/j.rcreu.2021.02.002
M3 - Artículo de revisión
AN - SCOPUS:85105427355
SN - 0121-8123
JO - Revista Colombiana de Reumatologia
JF - Revista Colombiana de Reumatologia
ER -
